Arthritis & Rheumatology 2004: Vol 51 Index

2004·3.7 MB·English

AUTHOR INDEX
Arthritis Care & Research, Volume 51, Numbers 1-6, 2004
A Bligny D, 83, 869 Community Hypertension and Fautrel B, 507
Bloch A, 670 Arthritis Project (CHAP), Favalli EG, 301
Abad S, 974 Boiardi L, 177 203 Feinglass J, 110
Abbey SE, 890 Boldrini M, 475 Concato J, 210 Feldman BM, 365, 881
Accardo P, 177 Bombardier C, 203, 874 Cooley DA, 228 Feldman DE, 527
Adam P, 909 Bono B, 140 Cooper C, 642 Felson DT, 371
Aeschlimann A, 819 Boomsma MM, 269 Cornell JE, 399 Fessler BJ, 73, 258, 465, 609
Ahern FM, 326 Boonen A, 433 Coste J, 168, 519 Fifield J, 239
Alarcén GS, 73, 258, 465, 609 Boshuizen HC, 440, 578 Costenbader KH, 983 Filippini D, 177
Alberini JL, 974 Bouzubar F, 40 Cott CC, 909 Fine M, 700
Albert D, 656 Bowyer SL, 365 Coyte PC, 635 Finol Y, 377
Aldag JC, 513 Bradley jD, 933 Creemers MCW, 124 Fisher MN, 34
Allaire SH, 871 Brand R, 593 Croft PR, 755 Fitzcharles MA, 1004
Allali J, 974 Brandt KD, 716, 933 Crowson CS, 264 Fitzgerald GK, 40, 941
Allison JJ, 337 Breedveld FC, 722 Cunningham J, 558 FitzGerald J, 679
Al Snih S, 34 Brennan MT, 505, 601 Cupps T, 558 Fitzgerald JD, 100
Ambrose K, 558, 700 Brensinger CM, 656 Curhan GC, 429, 1023 Fleegler E, 140
American College of Brézin AP, 974 Cush J, 228 Flipo RM, 507
Rheumatology Ad Hoc Briancgon S, 782 Cutolo M, 989 Foley SM, 422
Committee on Immunologic Brouwer WBF, 570 Fordiguez MA, 377
Testing Guidelines, 1030 Brower LM, 805 Fossel AH, 501, 1009
Amin §, 371 Brown AK, 1018 D Fox KR, 958
Amir H, 110 Bruce B, 730 Fox PC, 505, 601
Amor-Dorado JC, 274, 652 Brunner HI, 763, 899 Da Costa D, 1004 Fraenkel L, 210
Anderson LA, 215 Brydson G, 958 Dadoniene J, 433 Fransen J, 124, 388
Andrew T, 160 Buratti S, 458 D'Agostino D, 475 Franssen M, 299
Angst F, 819 Burckhardt CS, 864 Daltroy LH, 63 French Quality of Life Study
Anim-Appiah D, 140 Burke LE, 422 Davies K, 284 Group, 168, 519
Anis AH, 909 Buskens E, 488 Davis JC, 1 French Vasculitis Study
Antitinez A, 377 Davis J Jr., 302 Group, 482, 1061
Appleton BE, 498 de Civita M, 527 Friedman AW, 73, 258, 465,
Aries PM, 868 Dehueck A, 890 609
Arnoldi C, 301 C de Jong Z, 593 Fried T, 210
AAArutrlaetmgmahanin n iS ,R M, 1,4 7 7340 1 CCaanbtrianli DAF,, 127272 dDee kkKeery seJr, 7F2,2 691 FFrriitezsl eJr, 7M3,0 291
Aymé S, 92 Canvin J, 738 del Rincén I, 399 Frosch DL, 28
del Rosso A, 475
Carmona Ortells L, 184
Demange V, 782
Casale R, 665
de Pablo P, 1009
Chacén JG, 377 Devita P, 562 G
Chalmers A, 843
de Witte LP, 605
Chang HJ, 117 Gabriel SE, 264
Backman C, 792, 874 Chang RW, 110, 246 Dhillon SS, 681 Gambari PF, 989
Dhote R, 974
Badley EM, 635, 909 Chaudhry U, 505 Ganiats TG, 28
Baeten D, 691 Cheang M, 222 Dinant HJ, 440, 570, 578 Garcia-Castela A, 447
Baethge BA, 73, 258, 465, 609 Chiou CF, 358 Dobkin PL, 527 Garcia-Martinez A, 674
Baldwin N, 763 Chiu KY, 20 Docken WP, 868 Garcia-Porrua C, 274, 447, 652
Ballinger SH, 365 Choi HK, 1023 Doeglas D, 782 Garcia Velayos Y, 184
Balluz L, 533 Christian CL, 1060 Dominick KL, 326 Garry J, 562
Balshaw R, 746 Chu EMY, 20 Domitrovich PP, 700 Generini S, 475, 665
Barlas S, 746 Cibere J, 738 Doria A, 989 Genovese M, 228
Baron JA, 829, 836 Ciccia F, 177 Dougados M, 154 Geusens P, 549
Barrett J, 829, 836 Cid MC, 674 Dritsa M, 1004 Ghanem NA, 1062
Barron AC, 763, 899 Cieza A, 917 Duarte-Salazar C, 458 Ghirardello A, 989
Bastian HM, 73, 258, 465, 609 Clarkin C, 656 Duffy C, 527 Ghirarduzzi A, 177
Baumann M, 782 Clauw DJ, 558, 700 Dunbar-Jacob J, 422 Gibbon M, 527
Baum BJ, 505 Club Rhumatisme & Gignac MAM, 909
Beier J, 549 Inflammation of the French Giraudet AL, 974
Benito-Garcia E, 1030 Society for Rheumatology, Gitton X, 549
Bennett JA, 864 507 Eaton HM, 63 Giuliano AJ, 239
Beristain-Manterola R, 458 Coblyn JS, 383 Ecosse E, 519 Gold CH, 326
Berlin JA, 656 Coggon D, 642 Ellison MC, 810 Goldman L, 100
Bernstein B, 458 Cohen P, 482, 1061 Emery P, 1018 Gonzalez-Gay MA, 274, 447,
Bielefeld P, 482 Cohen §S, 228 Escalante A, 399 652
Bijlsma JWJ, 233, 488 Cohen Tervaert JW, 269 Esdaile JM, 738, 843 Gonzalez Hernéndez T, 184
Bischoff-Ferrari HA, 829 Committee for the Gonzalez-Juanatey C, 447
Blaauw AAM, 488 Standardization of F Gonzalez ME, 377
Blaivas M, 498 Autoantibodies in Gonzalez NE, 377
Blanche P, 974 Rheumatic and Related Falcini F, 458 Goodwin JS, 34
Bley TA, 1062 Diseases, 291 Farrell MJ, 558 Cordon C, 78
1086
AUTHOR INDEX
Arthritis Care & Research, Volume 51, Numbers 1-6, 2004
A Bligny D, 83, 869 Community Hypertension and Fautrel B, 507
Bloch A, 670 Arthritis Project (CHAP), Favalli EG, 301
Abad S, 974 Boiardi L, 177 203 Feinglass J, 110
Abbey SE, 890 Boldrini M, 475 Concato J, 210 Feldman BM, 365, 881
Accardo P, 177 Bombardier C, 203, 874 Cooley DA, 228 Feldman DE, 527
Adam P, 909 Bono B, 140 Cooper C, 642 Felson DT, 371
Aeschlimann A, 819 Boomsma MM, 269 Cornell JE, 399 Fessler BJ, 73, 258, 465, 609
Ahern FM, 326 Boonen A, 433 Coste J, 168, 519 Fifield J, 239
Alarcén GS, 73, 258, 465, 609 Boshuizen HC, 440, 578 Costenbader KH, 983 Filippini D, 177
Alberini JL, 974 Bouzubar F, 40 Cott CC, 909 Fine M, 700
Albert D, 656 Bowyer SL, 365 Coyte PC, 635 Finol Y, 377
Aldag JC, 513 Bradley jD, 933 Creemers MCW, 124 Fisher MN, 34
Allaire SH, 871 Brand R, 593 Croft PR, 755 Fitzcharles MA, 1004
Allali J, 974 Brandt KD, 716, 933 Crowson CS, 264 Fitzgerald GK, 40, 941
Allison JJ, 337 Breedveld FC, 722 Cunningham J, 558 FitzGerald J, 679
Al Snih S, 34 Brennan MT, 505, 601 Cupps T, 558 Fitzgerald JD, 100
Ambrose K, 558, 700 Brensinger CM, 656 Curhan GC, 429, 1023 Fleegler E, 140
American College of Brézin AP, 974 Cush J, 228 Flipo RM, 507
Rheumatology Ad Hoc Briancgon S, 782 Cutolo M, 989 Foley SM, 422
Committee on Immunologic Brouwer WBF, 570 Fordiguez MA, 377
Testing Guidelines, 1030 Brower LM, 805 Fossel AH, 501, 1009
Amin §, 371 Brown AK, 1018 D Fox KR, 958
Amir H, 110 Bruce B, 730 Fox PC, 505, 601
Amor-Dorado JC, 274, 652 Brunner HI, 763, 899 Da Costa D, 1004 Fraenkel L, 210
Anderson LA, 215 Brydson G, 958 Dadoniene J, 433 Fransen J, 124, 388
Andrew T, 160 Buratti S, 458 D'Agostino D, 475 Franssen M, 299
Angst F, 819 Burckhardt CS, 864 Daltroy LH, 63 French Quality of Life Study
Anim-Appiah D, 140 Burke LE, 422 Davies K, 284 Group, 168, 519
Anis AH, 909 Buskens E, 488 Davis JC, 1 French Vasculitis Study
Antitinez A, 377 Davis J Jr., 302 Group, 482, 1061
Appleton BE, 498 de Civita M, 527 Friedman AW, 73, 258, 465,
Aries PM, 868 Dehueck A, 890 609
Arnoldi C, 301 C de Jong Z, 593 Fried T, 210
AAArutrlaetmgmahanin n iS ,R M, 1,4 7 7340 1 CCaanbtrianli DAF,, 127272 dDee kkKeery seJr, 7F2,2 691 FFrriitezsl eJr, 7M3,0 291
Aymé S, 92 Canvin J, 738 del Rincén I, 399 Frosch DL, 28
del Rosso A, 475
Carmona Ortells L, 184
Demange V, 782
Casale R, 665
de Pablo P, 1009
Chacén JG, 377 Devita P, 562 G
Chalmers A, 843
de Witte LP, 605
Chang HJ, 117 Gabriel SE, 264
Backman C, 792, 874 Chang RW, 110, 246 Dhillon SS, 681 Gambari PF, 989
Dhote R, 974
Badley EM, 635, 909 Chaudhry U, 505 Ganiats TG, 28
Baeten D, 691 Cheang M, 222 Dinant HJ, 440, 570, 578 Garcia-Castela A, 447
Baethge BA, 73, 258, 465, 609 Chiou CF, 358 Dobkin PL, 527 Garcia-Martinez A, 674
Baldwin N, 763 Chiu KY, 20 Docken WP, 868 Garcia-Porrua C, 274, 447, 652
Ballinger SH, 365 Choi HK, 1023 Doeglas D, 782 Garcia Velayos Y, 184
Balluz L, 533 Christian CL, 1060 Dominick KL, 326 Garry J, 562
Balshaw R, 746 Chu EMY, 20 Domitrovich PP, 700 Generini S, 475, 665
Barlas S, 746 Cibere J, 738 Doria A, 989 Genovese M, 228
Baron JA, 829, 836 Ciccia F, 177 Dougados M, 154 Geusens P, 549
Barrett J, 829, 836 Cid MC, 674 Dritsa M, 1004 Ghanem NA, 1062
Barron AC, 763, 899 Cieza A, 917 Duarte-Salazar C, 458 Ghirardello A, 989
Bastian HM, 73, 258, 465, 609 Clarkin C, 656 Duffy C, 527 Ghirarduzzi A, 177
Baumann M, 782 Clauw DJ, 558, 700 Dunbar-Jacob J, 422 Gibbon M, 527
Baum BJ, 505 Club Rhumatisme & Gignac MAM, 909
Beier J, 549 Inflammation of the French Giraudet AL, 974
Benito-Garcia E, 1030 Society for Rheumatology, Gitton X, 549
Bennett JA, 864 507 Eaton HM, 63 Giuliano AJ, 239
Beristain-Manterola R, 458 Coblyn JS, 383 Ecosse E, 519 Gold CH, 326
Berlin JA, 656 Coggon D, 642 Ellison MC, 810 Goldman L, 100
Bernstein B, 458 Cohen P, 482, 1061 Emery P, 1018 Gonzalez-Gay MA, 274, 447,
Bielefeld P, 482 Cohen §S, 228 Escalante A, 399 652
Bijlsma JWJ, 233, 488 Cohen Tervaert JW, 269 Esdaile JM, 738, 843 Gonzalez Hernéndez T, 184
Bischoff-Ferrari HA, 829 Committee for the Gonzalez-Juanatey C, 447
Blaauw AAM, 488 Standardization of F Gonzalez ME, 377
Blaivas M, 498 Autoantibodies in Gonzalez NE, 377
Blanche P, 974 Rheumatic and Related Falcini F, 458 Goodwin JS, 34
Bley TA, 1062 Diseases, 291 Farrell MJ, 558 Cordon C, 78
1086
Gordon TP, 291 Ike RW, 498 Lafforgue P, 507 Marcantonio ER, 100
Gorman JD, 1 Imbert B, 482 Lahita RG, 291, 1030 Marchesoni A, 301
Gouya H, 974 Inman RD, 316 Lambert RGW, 681 Marin F, 377
Gowans SE, 890 lori I, 177 Lam C, 881 Martini A, 458
Goyert J, 792 lorio A, 177 Landewé R, 154 Marwaha J, 881
Grabar S, 974 Irrgang JJ, 40, 941 Landewe RBM, 1 Matteson EL, 853
Gracely RH, 558, 700 Iversen MD, 63, 305, 874 Lane KA, 933 Matucci-Cerinic M, 475, 665
Graham GB, 899 Langer M, 1062 Mazzuca SA, 716, 933
Granados I, 377 Langford CA, 278 McCall M, 422
Granados J, 147 Larroche C, 482 McCune WJ, 498
Grant E, 738 La Tourette AM, 383 McGibbon CA, 371
Grau JP, 674 Jackson JL, 9 Lau CS, 20 McGwin G Jr., 73, 258, 465,
Greco CM, 625 Jacobi CE, 440, 578 Lau VP, 332 609
Griffin TA, 763, 899 Jacobs JWG, 233, 488 LaValley MP, 371 McKinley K, 253
Griffiths B, 14 Jakez-Ocamp J, 147 Leakan RA, 505, 601 McLimont M, 881
Grisius M, 601 Jansen LM, 593 Lee C, 746 McPherson KM, 350
Groess! EJ, 28 Jhangri GS, 681 Lee M, 358 Mehta PS, 117
Grom AA, 899 Johns KR, 78 Lee TH, 100 Meir K, 670
Gross WL, 868 Johnson AL, 763 Lee TL, 899 Meldrum RD, 716
Guillemin F, 168, 507, 519, Johnson GE, 408 Lefrangois G, 168 Merkesdal S, 774
782 Jones JG, 679 Lepore L, 458 Mevorach D, 670
Guillevin L, 83, 92, 482, 869, Jones K, 365 Le Toumelin P, 83 Meyssonier V, 974
1061 Jones KD, 864 Levy M, 836 Mielants H, 154
Gu J, 691 Jump RL, 239 Liang MH, 983 Mietus-Snyder M, 451
Juvenile Dermatomyositis Ligier S, 505, 601 Mikuls TR, 337
Disease Activity Li LC, 203, 874 Miller FW, 365
H Collaboration Group, 365 Lindsley CB, 365 Miller MJ. 763
Lingard EA, 829, 1009 Mittendorf T, 774
Hakkinen A, 56 Littlejohn GO, 151 Mohan N, 558
Hammond A, 874 Llorca J, 274, 447, 652 Mokdad A, 533
Handelmann §, 774 K Llorente L, 147 Monnet D, 974
Hannonen P, 56 Lockshin MD, 78 Moore A, 549
Hansen KE, 228 Kaaridinen H, 925 Lopponen T, 925 Moore T, 899
Harker JO, 332 Kamatani N, 321 Losada BR, 377 Moratalla Justo C, 184
Harrington TM, 253 Kaplan RM, 28 Losina E, 501, 829, 836, 1009 Moreland LW, 933
Harrison AA, 311 Karim Z, 1018 Loustaud-Ratti V, 482 Moriarty DG, 533
Hartman M, 964 Karlson EW, 429, 983 Lovell DJ, 763, 899 Morton SC, 193
Haskett S, 792 Katona IM, 365 Lubeck DP, 358 Moum T, 782
Hasler P, 549 Katz BP, 933 Luepongsak N, 371 Mountz JM, 513
Hass UAM, 413 Katz JN, 383, 501, 829, 836, LUMINA Study Group, 73, Mouthon L, 83
Hausfater P, 482 1009 258, 465, 609 Munneke M, 593
Katz PP, 586
Hawker GA, 635 Lundan T, 925 Murray KJ, 284
Kavanaugh AF, 291
Hayes JR, 365 Lund S, 302 Myers AR, 140
Hazes IMW, 593 Kaye O, 507 Luppi F, 665 Myers J, 350
Khamashta MA, 78
Heck LW, 933 Lurie I, 110
Khubchandani R, 284
Heering A, 722 Lyden A, 700
Heijnsdijk-Rouwenhorst L, Kingman A, 601
947 Kirwan JR, 1045 N
Kjenen I, 709
HHeelrlnear ndDeAz,- R3o2d6r iguez J, 674 KKlliepipne-lG itJHe,l m1a9n3 MS, 763 M NNeeuwgmeabnau eErD , A,2 5538 6
Herren DB, 819 Knight TK, 996 MacGregor AJ, 160 Nichol MB, 996
Heuft-Dorenbosch L, 154 Knols R, 388 Machold KP, 917 Niedermann K, 388
Hewett JE, 408 Kocheril SV, 498 MacLean CH, 193, 337, 538 Noorbaloochl S, 952
Hicks J, 365 Kok MR, 601 MacSween A, 958 Nordenskiéld U, 413
Hill J, 874
Komoroski J, 656 Maeno N, 458
Hoeksma HL, 722
Holbert D, 562 Konttinen Y, 475 Maetzel A, 203, 316
Holmes JL, 422 Koopmanschap MA, 570 Maguire L, 203 O
Kopec JA, 738 Maher NE, 501
Holmgren AR, 952
K6rkk6 J, 925 Mahomed NN, 829, 1009 O'Connor PJ, 1018
Hong P, 738
Kozora E, 810 Mahr A, 83, 92, 482, 869, Oddis CV, 933
Hoogendijk JE, 148
Krasilnikov I, 670 1061 Oen K, 222
Hootman JM, 533
Krebs DE, 371 Maillard SM, 284 Oettinger M, 49
Hortobagyi T, 562
Kress A, 763 Maillefert JF, 507 O'Fallon WM, 264
Horton R, 49
Kroenke K, 215 Maksymowych WP, 143, 681, Ofman J, 358
Huang F, 691
Kiicgiikdeveci AA, 14 691 Okoro CA, 533
Huber AM, 365
Kvien TK, 709 Maldonado I, 377 Olenginski TP, 253
Huelsemann JL, 774
Kwoh CK, 422 Maldonado T, 377 Olivieri I, 177
Hugenberg ST, 933
Malleson PN, 222, 527 Olivieri JJ, 337
Hughes GRV, 78
Hunder GG, 264, 868 L Malloy MJ, 451 O'Malley PG, 9
Mangione CM, 100, 679 Orav EJ, 100
I Laan RFJM, 964 Manheim LM, 110 Ortiz-Alvarez O, 527
Lacaille D, 843, 909 Mannion AF, 819 Osés Puche JJ, 184
Iaccarino L, 989 Lachenbruch PA, 365 Manny J, 505 Ostir GV, 34
Ignatius J, 925 La Corte R, 177 Manzi S, 625, 933 Owens M, 533
P Richaud-Pain Y, 147 Silaj A, 890 U
Rider LG, 365 Silingardi M, 177
Paediatric Rheumatology Riemsma RP, 1045 Simmen BR, 819 Uebelhart D, 388
International Trials Rihl M, 691 Simpson RT, 350 Uhlig T, 709
Organisation, 519 Ring A, 1004 Sinacore J, 246 Uribe AG, 258, 465, 609
Page MC, 716 Rivera Redondo J, 184 Singer J, 738 Utrecht Rheumatoid Arthritis
Paget S, 49 Roach N, 140 Singhal A, 228 Cohort Study Group, 488
Palejko G, 792 Robbins L, 49 Singh JA, 952
Palmer KT, 642 Roberts TE, 1018 Skogh T, 413 V
Panni B, 301 Robinson DB, 738 Slatkowsky-Christensen B,
Paolazzi G, 177 Rocio Maldonado-Velazquez 709 Vaith P, 1062
Pap G, 819 M, 458 Slaughter JR, 408 Valdepefias Moraleda F, 184
Parc C, 974 Rollot F, 974 Sloan VS, 549 Vallejo Pareja MA, 184
Parke FA, 800 Ronday HK, 593, 722 Slot MC, 269 van de Berg B, 570
Parker JC, 408 Roos EM, 829 Smadja D, 482 VandeCreek L, 49
Passo MH, 365, 763, 899 Roseman JM, 73, 465, 609 Smarr KL, 408 van den Bos GAM, 440, 570,
Patel SK, 549 Rosenberg A, 117 Smith JA, 505, 601 578
Patel SR, 228 Rosenberg AM, 222 Smolen JS, 917 van den Ende CHM, 593, 722
Patino F, 337 Roudier J, 482 Sneller MC, 278 van den Heuvel WJA, 782
Paul H, 377 Rubinger D, 670 Soep JB, 451 van de Putte L, 299
Paulus HE, 358 Rudy TE, 625 Sokka T, 56 van der Heijde DMFM, 1, 154
Peat G, 755 Ruffatti A, 989 Solomon DH, 193, 383, 429 van der Lubbe N, 722
Pencharz JN, 203, 538 Ruiz-lIrastorza G, 78 Spector TD, 160 van der Tempel H, 154
Penroid JR, 507 Ruiz Zubero J, 184 Spencer CH, 458 van de Vlekkert J, 148
Perez MD, 365 Ruof J, 774 Spinelli JJ, 843 VanDyke MM, 408
Perruquet JL, 253 Ruperto N, 458 Spoorenberg A, 154 van Everdingen AA, 233
Pesce F, 974 Rupp I, 440, 578 Stamm TA, 917 van Exel NJA, 570
Petersson IF, 874 Russell AS, 681 Starz TW, 40, 422 van Holsbeck M, 877
Petitjean P, 482 Stegeman CA, 269 van Kessel M, 299
PPeettttyy -RSEa,p h2o2n2 S, 716 S SStteeinns tPrKé,m 7C0,0 874 vvaann LRiaenlk vPeLlCdM ,W , 12249,9 964
PPPPPPPPPPPhiihllioooiisviaalniog1ltccalltsln0ioii leiseo0brddimko S9eniiipeanrRo esJrket, L itG G ,CA , PA4S,B L8,A0R ,M,I4 0,,, , ,475 4 5 53 57592058 54904710 ,1271 5 , 5 , 68662509 1, 836, SSSSSSSSSSSaaaaaaaaaaallcchcaemmmvvkkikgepmbiassn d sarr KeKraoFG,HJlnHiS,o, ,,i , Atk 3 6 ,1a S086 711n,C218749P ,o5 1 3N 1 1 ,,391 37L 73,1,3 6 770 82 64 SSSSSSSSSSuttzttttuulraruoorunlilacnnoridnaukeep mtesai ue ArviMJ,TaAWGijH A,Wm,L,ee9 , , u,nr8 69 re 19712 t 305T778h1 3,4 SP6y3 6,B 1M40S3,6,3 4 272882 vvvVVVVVVVVaaéaeieeleennllnlrnayra i kakss zll C tTSV ei,LaeTiucEs AM,jpnbh M,7 , rpea, 2 4oAerHa 237o,n4,g r75 i6 6 ed7 j9454n e 1S3,8 n 3M8W b A6MJu,0,,r 9 g 12 594418D 8J , 593
Poor G, 549 Samuel R, 140 Vliet Vlieland TPM, 593, 874
Pope J, 738 Sanchez-Guerrero J, 147 Vogel S, 746
PPPooorrstts e rLR H,,B , 1 037039 22 SSSaaannnkdcaohrve azl V ,M RL5,,0 52,57 386, 012 58 TTaaia l K,E , 491 045 vvVooonns s dSeSc,rh e8Sv9ce0hn u lEe,n b4u5r1 g JM, 774
Pouchot J, 168, 519 Santiago LG, 377 Takei S, 458
Pratsidou-Gertsi P, 458 Saraux A, 507 Talar-Williams C, 278 Ww
Proven A, 868 Sarzi-Puttini PC, 989 Tang WM, 20
Punzi L, 989 Savelkoul M, 605 Tarricone E, 989 Wakefield RJ, 1018
Scarpato A, 475 Taylor J, 899 Walker-Bone K, 642
Schiff M, 228 Taylor P, 110 Walker SE, 408
Schmidt D, 1062 Taylor WJ, 311, 350 Wallace CA, 365
Q Schnitzer TJ, 549, 746, 933 Tenenbaum F, 974 Wallace DJ, 996
Schur PH, 1030 Tennant A, 14 Wanders AJB, 1
Queyrel V, 482 Schwyzer HK, 819 Tennen H, 239 Ward MM, 307, 616
Scrimshaw SC, 117 ter Borg Ej, 488 Warrington KJ, 309
Semanik P, 246 Testa A, 447 Weatherall M, 350
Senftleber I, 549 Thomas E, 755 Webb A, 302
Seo P, 128, 1064 Thorne A, 738 Weinberger M, 215
Radfar L, 505, 601 Seppanen U, 925 Thyberg I, 413 Weisman MH, 28, 358, 996
Rao JK, 215 Sereika S, 422 Tijn-A-Ton MLR, 148 Welsing PMJ, 964
Rasker JJ, 947, 1045 Severens JL, 964 Tofferi JK, 9 West S, 810
Ravelli A, 458 Sharma L, 933 Toronto Arthroplasty Health Weyand CM, 853
Reading I, 642 Shatzel S, 332 Services Research White PH, 365
Reed AM, 365 Sheps S, 843 Consortium, 635 Wieben O, 1062
Reeves W, 291 Sherbourne CD, 358 Tosi S, 301 Wiik AS, 291
Reiff A, 458 Shi S, 996 Triemstra M, 440 Wilbur J, 246
Reinhold-Keller E, 868 Shoji A, 321 Triolo G, 177 Wilkie R, 755
Reisine S, 239 Sicard D, 974 Trombley M, 763 Williams DA, 558
Rennebohm RM, 365 Sieber WJ, 28 Tullar JM, 501 Wilson MR, 291
Reveille JD, 73, 258, 465, 609, Siewertsz van Reesema DR, Turesson C, 853 Wittink DR, 210
800 233 Twisk JWR, 124 Witztum JL, 451
1088
Wolfe F, 933 Y Yu DTY, 691 Zeidler H, 774
Wong AL, 332 Yunus MB, 513 Zemel LS, 365
Wong B, 681 Yamanaka H, 321 Zhang H, 691
Wong RWS, 20 Yang C, 691 Z Zhao M, 691
Woo PM, 284 Yocum DE, 933 Zijlstra TR, 947
Wright EA, 501, 983 Young CS, 513 Zambrano G, 377 Zoppi M, 475
Wright JG, 316, 635 Young N, 881 Zampieri S, 989 Zuijderduin WM, 593
SUBJECT INDEX
Arthritis Care & Research, Volume 51, Numbers 1-6, 2004
A Assistive devices, in RA, 413
Association of Rheumatology Health Professionals (ARHP), orga-
Acetaminophen, NSAIDs vs. acetaminophen for OA: efficacy and nization mentorship for 21st century, 305
safety of, 746 Atherosclerosis
ACR criteria, accrual of for SLE in ethnic groups, 609 RA, endothelial function and anti-TNFa treatment, 447
Adaptation, work changes for arthritis patients to preserve em- SLE, risks for in pediatric SLE, 451
ployment, 871, 909 Autoimmune serology, cutting edge diagnostics for rheumatology,
Adduction moment, and chronic knee pain in elderly, 371 291
Adherence, subject retention and adherence in trial of DMAOD, Autonomic nervous system, heart rate variability in FM and Gulf
933 War illness: sex effects on, 700
Adolescents, reflex sympathetic dystrophy in, 151 Azathioprine, ANCA-associated vasculitis, relapse rate and, 269
Advanced access model, implementation in rheumatology prac-
tice, 253
Aerobic exercise, for FM, 890
Affective disorder Back pain
fatigue and RA, 239 prognosis and quality of life in acute low back pain, 168
social support and depressive symptoms in RA, 586 twin study of, 160
African American population Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
attrition of in clinical trials, 422 MMP-3 and macrophage colony-stimulating factor 1 and AS
SLE, predicting poor compliance, 258 severity, 691
SLE, wealth and disease activity in, 73 in patients with peripheral arthritis, 154
Aging. See Older adults for PsA, 311
Alcohol consumption, beer, liquor, and wine consumption and Beer consumption, beer, liquor, and wine consumption and se-
serum uric acid level: NHANES III, 1023 rum uric acid level: NHANES Ii, 1023
Alveolitis, cyclophosphamide for, 665 Behcet's disease, factor V gene and prothrombin gene mutations
American College of Rheumatology (ACR) in, 177
accrual of ACR criteria for SLE in ethnic groups, 609 Biofeedback, stress reduction for SLE patients with pain, 625
proposed ACR-SLE battery, reliability and validity of, 810 Biomarkers, SSc, health-related quality of life as measured by
Analgesics, quality indicator set for, 337 Short Form 36: relationship with clinical and biological
Ankylosing spondylitis (AS) markers, 475
B27-derived self peptide, 143, Biomechanics, knee adduction moment and chronic knee pain in
etanercept for, efficacy of, 143 elderly, 371
etanercept for, open-label extension study, 302 Body image, physical self perceptions of women with RA, 958
infliximab for, 143 Burden of care, in RA, 570
MMP-3 and macrophage colony-stimulating factor 1 and dis- Button Test, content comparison based on International Classifi-
ease activity in, 691 cation of Functioning, Disability and Health, 917
pamidronate for, 143
peripheral arthritis and disease activity in, 154 C
responsiveness and discriminate measures in, 1
Canadian Occupational Performance Measure
symptomatic enthesopathy of shoulder in, 681
content comparison based on International Classification of
treatment response in, 316
Functioning, Disability and Health, 917
Antihyperuricemic therapy, serum urate level and recurrent at- Norwegian version: validity, responsiveness, and feasibility of
tacks of gout, 321 in hand OA, 709
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculi- Cancer screening, in RA patients, 429
tis, azathioprine therapy and relapse rate, 269 Capture-recapture analysis, prevalence of vasculitides in Paris, 92
Anti-RNP antibody testing, guidelines for, 1030 Cardiovascular care, in RA patients, 429
Anti-Sm immune testing, guidelines for, 1030 Cardiovascular disease, cardiac risk factor awareness and man-
Anti-tumor necrosis factor a (anti-TNFa) agement of in SLE, 983
in AS, responsiveness and discriminate measures of assess- Caregiving
ments, 1 burden of informal care related to RA, 570
for RA, 309 care research: CARE Conference, 874
for RA, endothelial function and, 447 Children. See also Juvenile
for RA with hepatitis C infection, 800 Childhood HAQ revised versions, 881
Anxiety, in RA, 408 Childhood Myositis Assessment Scale normal values, 365
Arthritis. childhood-onset arthritis: Arg’°-Cys mutation in procollagen
mainstream nonpharmacologic treatment of, 203 type II gene, 925
measuring quality in care of, 193, 337, 538 JLA, Childhood HAQ validity independent of age, 519
positive affect and disability among older Hispanics, 34 JRA, predictors of pain in, 222
unmet expectations among rheumatology patients, 215 juvenile onset SLE, quality of life in, 458
Arthritis Impact Measurement Scales 2, translation and validation juvenile onset SLE, risks for atherosclerosis in, 451
of Chinese version, 20 parent proxy reporting and health of children with chronic
Arthroplasty. See Joint replacement arthritis: measuring instruments, 763
Assessment. See also Measuring instruments China, Arthritis Impact Measurement Scales 2, translation and
responsiveness and discriminate measures in AS, 1 validation into Chinese, 20
Assessment of Motor and Process Skills, content comparison Chronic multisymptom illness, sex effects on heart rate variability
based on International Classification of Functioning, Disabil- in FM and Gulf War illness, 700
ity and Health, 917 Churg-Strauss syndrome, prevalence of in Paris, 92
Assessments in Ankylosing Spondylitis Working Group, respon- Clinical trials
siveness and discriminate measures in, 1 attrition of African American participants, 422
1090
Clinical trials (cont'd) Disability
OA, manual therapy and exercise therapy in hip OA, 722 among older Mexican Americans with arthritis, 34
OA, subject retention and adherence in trial of DMAOD, 933 OA, pain and deformity predict disability in knee OA, 558
RA, glucocorticoid effect may be masked, 233 RA, assistive devices in, 413
SS, dehydroepiandrosterone (DHEA) pilot study, 601 RA, latent variable approach to measurement of physical dis-
Cluster design, RA clinical decision support, cluster randomized ability, 399
controlled trial design, 124 RA, overview of work disability in, 488
Cognitive-behavioral therapy, for FM, 184 RA, relationship between support, limitations, and distress, 782
COL2A1 gene, childhood-onset arthritis: Arg’°-Cys mutation on, RA, social support and, 586
925 RA, work disability in, Lithuanian patients, 433
Combination therapy RA, work disability in, overview of, 488
anti-TNFa switching, safety and effectiveness of, 301 total hip replacement, functional status following, 829
RA, leflunomide with infliximab, 228 work changes to prevent, 871, 909
Communication Discriminative capacity, responsiveness and discriminate mea-
RA, influence of discussions on exercise prescriptions, 63 sures in AS, 1
unmet expectations among rheumatology patients, 215 Disease activity
Competency assessment, musculoskeletal ultrasonography, prac- AS, influence of peripheral arthritis on, 154
tice, training, and assessment: toward development of stan- AS, MMP-3 and macrophage colony-stimulating factor 1 and
dards, 1018 disease activity in, 691
Complementary and alternative medicine, use in JIA, 527 juvenile onset SLE, health-related quality of life and, 458
Complex regional pain syndrome, in adolescents, 151 peripheral arthritis, BASDAI for, 154
Compliance PsA, BASDAI for, 311
OA, subject retention and adherence in trial of DMAOD, 933 RA, glucocorticoid effect may be masked, 233
SLE, predicting poor compliance, 258 SLE, measuring during pregnancy, 78
Coping SLE, pregnancy, cytokines, and disease activity in, 989
RA, religious and nonreligious coping methods in, 49 SLE, wealth and disease activity in ethnic groups, 73
SSc, health-related quality of life measured by Short Form 36, Duruéz Hand Index, reliability and validity of in SSc, 805
475
Corticosteroids
E
in combination therapy for hepatitis B-related polyarteritis no-
dosa, 482, 1060, 1061 Education, SLE, education level and mortality, 616
in GCA, effect of statin use on, 674 Elderly. See Older adults
Cross-cultural validity Eligibility, ethnicity and eligibility in California SLE patients, 996
Arthritis Impact Measurement Scales 2, translation and valida- Employment. See Work; Work disability
tion of Chinese version, 20 Empowerment, Spanish-language arthritis empowerment pro-
Canadian Occupational Performance Measure in hand OA: Nor- gram, 332
wegian version, 709 Endothelial function
HAQ, Turkish adaptation of, 14 RA, anti-TNFa treatment and, 447
Cyclobenzaprine, for FM, 9 SLE, pediatric-onset, 451
Cyclooxygenase 2 (COX-2) inhibitors Enthesopathy, symptomatic enthesopathy of shoulder in AS, 681
informed choice and use of, 210 Environmental toxins, WG pathogenesis and, 656
knee and hip OA, acetaminophen vs. NSAIDs: efficacy and Epidemiology, of GCA in Minnesota, 264
safety, 746 Erratum, 304
knee and hip OA, lumiracoxib vs. diclofenac, 549 Etanercept
quality indicator set for, 337 anti-TNFa switching, safety and effectiveness of, 301
rofecoxib case report: renal failure and nephritis, 670 for AS, efficacy of. 143
Cyclophosphamide, in SSc, 665 for AS, open-label extension study, 302
Cytokines, pregnancy, and disease activity in SLE, 989 for AS, responsiveness and discriminate measures of assess-
ments, 1
Ethnicity
D
SLE, accrual of ACR criteria in, 609
Decision support, RA clinical decision support, cluster random- SLE, education level and mortality, 616
ized controlled trial design, 124 SLE, eligibility, utilization, and costs in California SLE patients,
Deep vein thrombosis, factor V gene and prothrombin gene mu- 996
tations in, 177 SLE, predicting poor compliance, 258
Deformity, pain and deformity predict disability in knee OA, 558 SLE, wealth and disease activity in ethnic groups, 73
Degos’ disease, mimics vasculitis, 498 total knee replacement, concerns of patients contemplating:
Dehydroepiandrosterone (DHEA), for SS, pilot study, 601 race and gender differences, 117
Depression Exercise. See also Physical activity
mental distress status among adults with arthritis age 45 years for FM, 184, 890
and older, 533 for hip OA, 722
RA, anxiety in, 408 RA, exercise trial participant characteristics, 593
RA, fatigue in RA and, 239, 578 RA, influence of discussions on exercise prescriptions, 63
RA, impact of social support on depressive symptoms, 586 SpA, fatigue intensity and leisure-time physical activity, 1004
Dermatomyositis (DM), Childhood Myositis Assessment Scale, Extraarticular rheumatoid arthritis (RA), genetics of, 853
365
Diagnosis F
accuracy of Veterans Administration databases for RA diagno-
sis, 952 Factor V Leiden mutation, in Behget’s disease and deep vein
anti-Sm and anti-RNP antibody tests, guidelines for laboratory thrombosis, 177
testing, 1030 Fatal cutaneous-intestinal syndrome, Degos’ disease mimics vas-
costs for workups for early RA, survey, 507 culitis, 498
cutting edge methods for rheumatology, 291 Fatigue
Diclofenac, in knee or hip OA, compared with lumiracoxib, 549 RA, affective disorder and, 239
Fatigue (cont'd) Health care use (cont'd)
RA, health-related quality of life and, 578 SLE, ethnicity and utilization in California SLE patients, 996
SpA, mental health status and leisure-time physical activity Health-related quality of life (HRQOL)
and, 1004 juvenile onset SLE, quality of life in, 458
Fever, in GCA, 652 OA, health service use among older adults and, 326
Fibromyalgia (FM) parent proxy reporting and health of children with chronic
aerobic exercise for, 890 arthritis: measuring instruments, 763
cyclobenzaprine treatment of, 9 RA, Cedars-Sinai Health-Related Quality of Life in Rheumatoid
exercise and cognitive-behavioral therapy in, 184 Arthritis (CSHQ-RA) short form instrument, 358
motivational interviewing in, 864 RA, fatigue and, 578
positron emission tomography in, 513 SLE, 465
sex effects on heart rate variability in, 700 SLE, juvenile, 458
Functional Dexterity Test, content comparison based on Interna- SSc, measured by Short Form 36, 475
tional Classification of Functioning, Disability and Health, Health status, unmet expectations among rheumatclogy patients,
917 215
Functional status, following total hip replacement, 329 Heart rate, sex effects in FM and Gulf War illness, 700
Heat therapy, in knee OA, 716
Heavy metal exposure, WG pathogenesis and, 656
G
Hepatitis B-related polyarteritis nodosa, therapeutic strategy for,
Gender 482, 1060, 1061
heart rate variability in FM and Guif War illness: sex effects on, Hepatitis C infection, anti-TNF for RA with hepatitis C infection,
700 800
total knee replacement, concerns of patients contemplating: Hip
race and gender differences, 117 OA, longitudinal comparison of HAQ with WOMAC, 730
Genetics OA, lumiracoxib vs. diclofenac in, 549
AS, MMP-3 and macrophage colony-stimulating factor 1 and OA, manual therapy and exercise therapy in, 722
disease severity, 691 OA, NSAIDs vs. acetaminophen: efficacy and safety, 746
Behcet's disease and deep vein thrombosis, factor V gene and OA, willingness to consider total joint arthroplasty, 635
prothrombin gene mutations in, 177 Hip replacement
childhood-onset arthritis: Arg”°-Cys mutation on procollagen determinants of discharge destination following, 1009
type II gene (COL2A1), 925 low-volume hospitals for, 836
low back and neck pain in twins, 160 psychosocial and geriatric correlates of functional status follow-
RA, pattern predicting extraarticular manifestations, 853 ing, 829
Gerontorheumatologic outpatient service, 299 quality of life following, 100, 679
Giant cell arteritis (GCA) Hispanic population
epidemiology of in Minnesota over 50-year period, 264 SLE, predicting poor compliance, 73
fever in, 652 SLE, wealth and disease activity in, 73
glucocorticoid therapy in, 868 Spanish-language arthritis empowerment program, 332
occult (silent) GCA, 274 Hospitals, low-volume hospitals for total hip replacement, 836
overview of, 128 Humoral immune response, SLE, pregnancy, cytokines, and dis-
statins in, 674 ease activity in, 989
temporal artery inflammation by MRI, 1062, 1064 Hyperuricemia
Glucocorticoid-induced osteoporosis, educational BCT for man- beer, liquor, and wine consumption and serum uric acid level:
agement of, 383 NHANES III, 1023
Glucocorticoids serum urate level and recurrent attacks of gout, 321
in GCA, 868
RA, glucocorticoid effect may be masked. 233 I
Glucosamine, knee OA, discontinuation trial, 738
Imaging
Gout
AS. MRI evaluation of shoulder in, 681
beer, liquor, and wine consumption and serum uric acid level:
Degos’ disease mimics vasculitis, 498
NHANES III, 1023
FM, positron emission tomography in, 513
serum urate level and recurrent attacks of, 321
GCA, temporal artery inflammation by MRI, 1062, 1064
Gulf War illness, sex effects on heart rate variability in, 700
large-vessel vasculitis, 130
low back and neck pain in twins, 160
Immunologic testing guidelines, anti-Sm and anti-RNP antibody
test guidelines, 1030
Hand
Inflammation, temporal artery inflammation in GCA by MRI,
Mycobacterium avium complex tenosynovitis of, 140 1062, 1064
OA, Canadian Occupational Performance Measure, validity, re- Infliximab
sponsiveness, and feasibility of Norwegian version, 709 anti-TNFa switching, safety and effectiveness of, 301
RA, silver ring splints and hand dexterity in, 947 AS, 143
SSc, Duruéz Hand Index, reliability and validity of, 805 AS, MMP-3 and macrophage colony-stimulating factor 1 in, 691
Health Assessment Questionnaire (HAQ) AS, treatment response in, 316
Childhood HAQ in JIA, validity independent of age, 519 RA, combination therapy with leflunomide and infliximab, 228
Childhood HAQ revised versions, sensitivity of, 881 RA, endothelial function and anti-TNFa treatment, 447
cross-cultural validity of Turkish version, 14 Informal care, RA, burden of informal care, 570
longitudinal comparison with WOMAC, 730 Italian popuiation, Behcet's disease, factor V gene and prothrom-
Health care preferences, JIA: parent willingness-to-pay technique, bin gene mutations in, 177
feasibility and construct validity of, 899
Health care use
J
OA, health-related quality of life and health service use among
older adults, 326 Jebson Taylor Hand Function Test, content comparison based on
RA, patient-reported utilization, 774 International Classification of Functioning, Disability and
RA, unmet health care demands in, 440 Health, 917
1092
Joint instability, in knee OA, 941 LUMINA study
Joint replacement SLE, accrual of ACR criteria in ethnic groups, 609
total hip replacement, determinants of discharge destination SLE, predicting poor compliance, 258
following, 1009 SLE, wealth and disease activity in ethnic groups, 73
total hip replacement, low-volume hospitals for, 836 Lumiracoxib, in knee or hip OA, compared with diclofenac, 549
total hip replacement, patient quality of life following, 100, 679 Lupus Activity Index in Pregnancy (LAI-P), validation of, 78
total hip replacement, psychosocial and geriatric correlates of
functional status after, 829
total knee replacement, concerns of patients contemplating: M
race and gender differences, 117
Macrophage colony-stimulating factor 1, AS, disease activity and,
total knee replacement, patient quality of life following, 100,
691
679
Magnetic resonance imaging (MRI)
total knee replacement, perioperative complication rates in II-
AS, symptomatic enthesopathy of shoulder in, 681
linois, 110
GCA, temporal artery inflammation by, 1062, 1064
total knee replacement, willingness to consider, 635
low back and neck pain in twins, 160
total shoulder replacement. outcome and quality of life after,
Malignant atrophic populosis, Degos’ disease mimics vasculitis,
819
498
Juvenile idiopathic arthritis (JIA)
Manual therapy, in hip OA, 722
Childhood HAQ validity independent of age, 519
Matrix metalloproteinase 3 (MMP-3), AS, disease activity and,
complementary and alternative medicine in, 527
691
parent willingness-to-pay technique, feasibility and construct
Measuring instruments. See also Assessment
validity of, 899
Arthritis Impact Measurement Scales 2, translation and valida-
Juvenile idiopathic inflammatory myopathies, Childhood Myosi-
tion of Chinese version, 20
tis Assessment Scale, 365
Assessment of Motor and Process Skills, content comparison
Juvenile onset SLE
based on International Classification of Functioning, Disabil-
atherosclerosis risk and endothelial function in, 451
ity and Health, 917
health-related quality of life and disease activity and organ
BASDAI, 154, 311
damage, 458
Button Test, content comparison based on International Classi-
Juvenile rheumatoid arthritis (JRA)
fication of Functioning, Disability and Health, 917
anti-TNFa switching, safety and effectiveness of, 301
Canadian Occupational Performance Measure, content compar-
predictors of pain, 222
ison based on International Classification of Functioning, Dis-
ability and Health, 917
K Canadian Occupational Performance Measure, Norwegian ver-
sion: validity, responsiveness, and feasibility of in hand OA,
Kidneys, rofecoxib case report: renal failure and nephritis, 670 709
Knee Cedars-Sinai Health-Related Quality of Life in Rheumatoid Ar-
adduction moment and chronic knee pain in elderly, 371 thritis (CSHQ-RA) short form instrument, 353
OA, glucosamine discontinuation trial, 738 Childhood HAQ in JIA, validity independent of age, 519
OA, heat therapy in, 716 Childhood HAQ revised versions, sensitivity of, 881
OA, informed choice and use of NSAIDs, 210 Childhood Myositis Assessment Scale normal values, 365
OA, joint instability and, 941 clinical outcome and quality of life following total shoulder
OA, longitudinal comparison of HAQ with WOMAC, 730 arthroplasty, 819
OA, lumiracoxib vs. diclofenac in, 549 comparison of occupation-based instruments based on Interna-
OA, NSAIDs vs. acetaminophen: efficacy and safety, 746 tional Classification of Functioning, Disability and Health,
OA, pain and deformity predict disability in, 558 917
OA, perception of quality of life and, 377 Duruéz Hand Index, reliability and validity of in SSc, 805
OA, quadriceps activation failure in, 40 Functional Dexterity Test, content comparison based on Inter-
OA, quadriceps control in, 562 national Classification of Functioning, Disability and Health,
OA, willingness to consider total joint arthroplasty, 635 917
Knee replacement HAQ, cross-cultural validity of Turkish version, 14
concerns of patients contemplating: race and gender differ- HAQ and WOMAC, 730
ences, 117 health-related quality of life (HRQOL), parent proxy reporting
patient quality of life following, 100, 679 and health of children with chronic arthritis, 763
perioperative complication rates in Illinois, 110 Jebson Taylor Hand Function Test, content comparison based
willingness to consider, 635 on International Classification of Functioning, Disability and
Health, 917
L joint pain in OA: levels of participation in surveys, 755
latent variable approach to measurement of physical ability in
Lamivudine, in combination strategy for hepatitis B-related poly- RA, 399
arteritis nodosa, 482, 1060, 1061 Lupus Activity Index in Pregnancy (LAI-P), validation of, 78
Latent variable approach, to measurement of physical ability in Moberg Picking Up Test, content comparison based on Interna-
RA, 399 tional Classification of Functioning, Disability and Health,
Lead exposure, WG pathogenesis and, 656 917
Leflunomide patient-reported health care utilization in RA, 774
modeling of cost effectiveness of TNF-blocking agents for RA Physical Self-Perception Profile (PSPP) and Perceived Impor-
treatment, 964 tance Profile (PIP), reliability and validity of in women with
RA, combination therapy with leflunomide and infliximab, 228 RA, 958
RA, weekly leflunomide for recent-onset disease, 147 proposed ACR-SLE battery, reliability and validity of, 810
Liquor consumption, beer, liquor, and wine consumption and quality measurement in arthritis care, 193, 337
serum uric acid level: NHANES III, 1023 Quality of Well-Being Scale in musculoskeletal disease, validity
Lithuania, RA, work disability in Lithuania, 433 of, 28
Low back pain Sequential Occupational Dexterity Assessment, content com-
prognosis and quality of life in acute low back pain, 168 parison based on International Classification of Functioning,
twin study, 160 Disability and Health, 917
1093
Measuring instruments. See also Assessment (cont'd) O
Short Form 36 for SSc, relationship with clinical and biological
Occult (silent) arteritis, overview of, 274
markers, 475
Occupational therapy, comparison of occupation-based instru-
World Health Organization Quality of Life Instrument (WHO-
ments based on International Classification of Functioning,
QOL-BREF) for RA patients, 350
Disability and Health, 917
Medical costs
Older adults
RA, modeling of cost effectiveness of TNF-blocking agents for,
adduction moment and chronic knee pain in, 371
964
gerontorheumatologic outpatient service, 299
RA, workup cost for diagnosis of early disease, 507
OA, health-related quality of life and health service use among
SLE, ethnicity and costs in California SLE patients, 996
older adults, 326
Mental health
positive affect and disability among older Mexican Americans
mental distress status among adults with arthritis age 45 years
with arthritis, 34
and older, 533
total hip replacement, functional status following, 829
RA, fatigue and affective disorder in, 239 Organ damage, juvenile onset SLE, health-related quality of life
RA, impact of social support on depressive symptoms, 586 and, 458
SpA, fatigue intensity and mental health status, 1004 Orthoses
Mercury exposure, WG pathogenesis and, 656 RA, silver ring splints and hand dexterity, 947
Mexican American population, positive affect and disability wrist splints for adults with inflammatory arthritis, 792
among older patients with arthritis, 34 Osteoarthritis (OA)
Microarrays, AS, MMP-3 and macrophage colony-stimulating fac- hand, Canadian Occupational Performance Measure, validity,
tor 1 in, 691 responsiveness, and feasibility of Norwegian version, 709
Microscopic polyangiitis, prevalence of in Parisian suburb, 92 HAQ and WOMAC, longitudinal comparison of, 730
Minority groups. See Ethnicity health-related quality of life and health service use among older
Moberg Picking Up Test, content comparison based on Interna- adults, 326
tional Classification of Functioning, Disability and Health, hip, longitudinal comparison of HAQ with WOMAC, 730
917 hip, lumiracoxib vs. diclofenac in, 549
Modeling, cost effectiveness of TNF-blocking agents for RA treat- hip, NSAIDs vs. acetaminophen: efficacy and safety, 746
ment, 964 hip, OA, manual therapy and exercise therapy in, 722
Mortality hip, willingness to consider total joint arthroplasty, 635
SLE, education level and, 616 knee, adduction moment and chronic knee pain in elderly, 371
WG, predicting, 83, 868, 869 knee, glucosamine discontinuation trial, 738
Motivational interviewing, in FM, 864 knee, heat therapy in, 716
Muscle strength knee, informed choice and use of NSAIDs, 210
Childhood Myositis Assessment Scale normal values, 365 knee, joint instability and, 941
knee OA, quadriceps control in, 562 knee, longitudinal comparison of HAQ with WOMAC, 730
RA, long-term benefits of strength training in early disease, 56 knee, lumiracoxib vs. diclofenac in, 549
Musculoskeletal disease knee, NSAIDs vs. acetaminophen: efficacy and safety, 746
Quality of Well-Being Scaie in musculoskeletal disease, validity knee, pain and deformity predict disability in, 558
of, 28 knee, perception of quality of life and, 377
reflex sympathetic dystrophy in adolescents, 151 knee, quadriceps activation failure in, 40
Musculoskeletal disorders, prevalence of upper limb musculo- knee, quadriceps control in, 562
skeletal disorders in general population, 642 knee, willingness to consider total joint arthroplasty, 635
Musculoskeletal manipulation, in hip OA, 722 lumiracoxib vs. diclofenac in, 549
Musculoskeletal ultrasonography measuring joint pain: levels of participation in surveys, 755
practice, training, and assessment: toward development of stan- measuring quality in arthritis care, 193, 337, 538
dards, 1018 nonpharmacologic treatment of, 203
review, 877 NSAIDs vs. acetaminophen for, 746
Mutations subject retention and adherence in trial of disease-modifying
Behcet's disease and deep vein thrombosis, factor V gene and drug, 933
willingness to consider total joint arthroplasty, 635
prothrombin gene mutations in, 177
Osteoporosis, educational BCT for management of glucocorticoid-
childhood-onset arthritis: Arg”"-Cys mutation on procollagen
induced osteoporosis, 383
type II gene (COL2A1), 925
Outcomes
Mutual support groups, in rheumatic diseases, 605
AS, treatment response in, 316
Mycobacterium avium complex, tenosynovitis of wrist and hand,
quality of life following joint replacement surgery, 100, 679
140
total hip replacement, psychosocial and geriatric correlates of
Mycophenolate mofetil, for remission maintenance in WG, 278
functional status after, 829
Myositis, Childhood Myositis Assessment Scale, 365
of total shoulder replacement, 819
P
N
Pain
Neck pain, twin study, 160 JRA, predictors of pain in children, 222
Nephritis, with rofecoxib use: case report, 670 knee adduction moment and chronic knee pain in elderly, 371
Neuropsychiatric systemic lupus erythematosus (SLE), proposed low back and neck pain, genetic contribution to, 160
ACR-SLE battery, reliability and validity of, 810 OA, measuring joint pain: levels of participation in surveys, 755
Nonpharmacologic treatment OA, pain and deformity predict disability in knee OA, 558
FM, exercise and cognitive-behavioral therapy, 184 SLE, stress-reduction program for patients with pain, 625
OA, manual therapy and exercise therapy in hip OA, 722 upper limb musculoskeletal disorders, prevalence of in general
OA and RA, 203 population, 642
Nonsteroidal antiinflammatory drugs (NSAIDs) wrist splints for adults with inflammatory arthritis, 792
informed choice and use of, 210 Pamidronate, for AS, 143
OA, acetaminophen vs. NSAIDs: efficacy and safety of, 746 Participation, joint pain in OA: levels of participation in surveys,
quality indicator set for, 337 755
1094